Диссертация (1140240), страница 16
Текст из файла (страница 16)
Bouloc A., Grange F. Delfau-Larue M.H., Dieng M.T., Tortel M.C., AvrilM.F., Revuz J., Bagot M., Wechsler J. Leucoderma associated with flares oferythrodermic cutaneous T-cell lymphomas: four cases. The French Study Groupof Cutaneous Lymphomas.// Br J Dermatol. 2000 Oct;143(4):832-6.56. Breathnach A. S., Bor S., Wyllie L. H. A., Electron microscopy of peripheralnerke ferminals and marginal melanocytes in Vitiligo // J. Invest Dermatol.
1966.Vol. 47.- P. 125.57. Brown J., Winklemann R.K., Wolff K. Langerhans cells in vitiligo: aqualitative study.// J Invest Dermatol. 1967 Oct;49(4):386-90.58. Bystryn J.C. Immune mechanisms in vitiligo.// Immunol Ser. 1989; 46: 447473. Review PMID: 2488866.59. Caron-Schreinemachers A.L., Kingswijk M.M., Bos J.D., Westerhof W.UVB 311 nm tolerance of vitiligo skin increases with skin photo type.// Acta DermVenereol. 2005;85(1):24-6.60. Cai-Xia T., Jin-Song G., Xi-Ran L. Increased interleukin-6 and granulocytemacrophage clony stimulating factor levels in the sera of patients with nonsegmental vitiligo // J.
Dermatol. Scien. – 2003. – N. 31. – P. 73-78.61. Chen G.Y., Hsu M.M., Tai H.K., Chou T.C., Tseng C.L., Chang H.Y., LanC.C., Sheu H.M. Narrow-band UVB treatment of vitiligo in Chinese. // J Dermatol.1042005; 32(10):793-800.62. Ciescinska C., Mazur A., Placek W. Autoimmunological etiology of vitiligoand alopecia areata//JEADV-2008-FP058463. Claudy A.L., Rouchouse B. Langerhans' cell and vitiligo: quantitative studyof T6 and HLA-DR antigen-expressing cells.// Acta Derm Venereol.1984;64(4):334-6.64. Cui J., Arita Y., Bystryn J.C. Cytolytic antibodies to melanocytes in vitiligo.//J Invest Dermatol.
1993 Jun;100(6):812-5.65. Dammak I., Boudaya S., Ben Abdallah F., Turki H., Attia H., Effect of dateseed oil on p53 expression in normal human skin//Connect Tissue Res.2010;51(1):55-8. \ doi: 10.3109/03008200902998709.66. El Mofty M., Mostafa W., Esmat S., Youssef R., Azzam O., Hunter N., ElHanafi G., Fawzi M.
Narrow band Ultraviolet B 311 nm in the treatment ofvitiligo: two right-left comparison studies.// Photodermatol PhotoimmunolPhotomed. 2006 Feb;22(1):6-11.67. Em S., Laddha N.C., Chatterjee S., Gani A.R., Malek R.A., Shah B.J.,Begum R. Association of catalase T/C exon 9 and glutathione peroxidase codon200 polymorphisms in relation to their activities and oxidative stress with vitiligosusceptibility in Gujarat population.// Pigment Cell Res. 2007 Oct;20(5):405-7.68.
Erf G.F., Bersi T.K., Wang X. Herpesvirus connection in the expression ofautoimmune vitiligo in Smyth line chickens // Pigment Cell Res. – 2001. – № 14. –P. 40-46.69. Ermis O., Alpsoy E., Cetin L., Yilmaz E. Is the efficacy of PUVA therapyfor vitiligo enhaneed by concurrent topical calcipotriol? A placebo-contr0lled anddouble-blind study. // Br J Dermatol 2001; 145(3): 472—475.70. Esposito M., Sada R., Costanzo A.
Treatment of vitiligo with the 308 nmeximer laser.// Clin. Exp. Dermatol. 2004. - V.29, n.2. - P.133-13771. Eves P.C., Bullett N.A., Haddow D. et al. Simplifying the delivery ofmelanocytes and keratinocytes for the treatment of vitiligo using a chemicallydefined carrier dressing // J. Invest. Dermatol. – 2008. – Vol. 128. – P.
1554-1564.10572. Fain P.R., Gowan K., LaBerge G.S., Alkhateeb A., Stetler G.L., Talbert J.,Bennett D.C., Spritz R.A. A genomewide screen for generalized vitiligo:confirmation of AIS1 on chromosome 1p31 and evidence for additionalsusceptibility loci. Am J Hum Genet. 2003 Jun;72(6):1560-4.
Epub 2003 Apr 18.73. Feldman S.R. Efficacy of the 308-nm excimer laser for treatment ofpsoriasis: results of a multicenter study / Feldman S.R., Mellen B.G., HousmanT.S. // J. Am. Acad. Dermatol. 2002. - V.46. - P.900-906.74. Gerber W., Arheilger B., Ha T.A., Hermann J., Ockenfels H.M. UltravioletB 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach.Br. J.
Dermatol. 2003; 149: 1250—125875. Goktas E.O., Aydin F., Senturk N., Canturk M.T., Turanli A.Y.Combination of narrow band UVB and topical calcipotriol for the treatment ofvitiligo.//J Eur Acad Dermatol Venereol 2006; 20: 55376. Greve B., Raulin C., Fischer E. Excimer laser treatment of vitiligo— criticalretrospective assessment of own results and literature overview. // J. Dtsch.Dermatol.
Ges. 2006. - V. 4, n.l. - P.32-40.77. Greve В., Raulin C., Fischer E. Eximer laser treatment of vitiligo -criticalretrospective assessment of own results and literature overview. J Dtsch DermatolGes. 2006; 4 (1): 32-40.78. Grimes P. E., Sanders Seva J., Vojdani A. Cytomegalovirus DNA identifiedin skin biopsy specimens of patients with vitiligo // J. Am. Acad. Dermatol. –1996.
– Vol. 35. – P. 21-26.79. Grimes P.E. White patches and bruised souls: advances in the pathogenesisand treatment of vitiligo///! Am. Acad. Dermatol. 2004,V.51, Suppl.l, S5-S7.80. Guan C.P., Zhou M.N., Xu A.E., Kang K.F., Liu J.F., Wei X.D., Li Y.W.,Zhao D.K., Hong W.S. The susceptibility to vitiligo is associated with NF-E2related factor2 (Nrf2) gene polymorphisms: a study on Chinese Han population.//Exp Dermatol. 2008 Dec;17(12):1059-62. doi: 10.1111/j.1600-0625.2008.00752.x.Epub 2008 Jun 4.81.
Gundogan C., Greve B., Raulin C. Treatment of alopecia areata with the 308106nm xenon chloride excimer laser: case report of two successful treatments with theexcimer laser. Lasers Surg Med. 2004; 34 (2): 86—9082. Gupta S., Goel A., Kanwar A.J., Kumar B. Autologous melanocyte transfervia epidermal grafts for lip vitiligo // Int. J. Dermatol. – 2006. – Vol. 45. – P. 747750.83. Hadi S.M., Spenser J.M., Lebwohl M. The use of the 308- nm eximer laserfor the treatment of vitiligo.// Dermatol.Surg. 2004. - V.30, n.7. - P.983-986.84. Halder R.M., Young C.M.
New and emerging therapies for vitiligo.//Dermatol.Clin. 2000; 18(1): 79—89.85. Hamzavi I., Jain H., McLean D., Shapiro J., Zeng H., Lui H. Parametricmodeling of narrowband UV-B phototherapy for vitiligo using a novel quantitativetool: The Vitiligo Area Scoring Index. // Arch Dermatol. 2004; 140: 677—68386. Hann S.K., Chun W.H., Park Y.K. Clinical characteristics of progressivevitiligo.// Int J Dermatol. 1997 May;36(5):353-5.87. Harning R., Cui J., Bystryn J.C. Relation between the incidence and level ofpigment cell antibodies and disease activity in vitiligo.// J Invest Dermatol. 1991Dec;97(6):1078-80.88. Hegediis L., Heidenheim M., Gervil M.
et al. High frequency of thyroiddysfunction in patient with vitiligo. // Acta Derm Venereol. 1994. V.74. -P.120123.89. Hexsel C.L., Eide M.J., Johnson C.C., Krajenta R., Jacobsen G., Hamzavi I.et al. Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. JAm Acad Dermatol 2009; 60: 929—933.90. Hofer A., Hassan A.S., Legat F.J., Kerl H., Wolf P. Optimal weeklyfrequency of 308-nm excimer laser treatment in vitiligo patients. // Br J Dermatol.2005 May;152(5):981-5.91. Huggins R.H., Schwartz R.A., Krysicka-Janniger C. Vitiligo //ActaDermatovenerol. Alp.
Panonica Adriat. 2005, V.14, No4, P.137-142,144-145.92. Iverson M.V. Hypothesis: Vitiligo virus // Pigment Cell Res. – 2000. – Vol.13. – P. 281-282.10793. Kao C.H., Hsen S.Y. Comparison of the effect of 8-methoxypsoralen (8MOP) puis UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro.// J Invest Dermatol, 1992,98:734-740.94.
Kao C.H., Yu H.S. Depletion and repopulation of Langerhans cells innonsegmental type vitiligo.// J Dermatol. 1990 May;17(5):287-96.95. Kekourou T. Vitiligo in children. World. J. Pediatr. 2009; 5(4): 265—268.96. Kemp E.H., Rezaei N., Gavalas N.G., Weetman A.P. Autoimmunity as anaetiologicalfactorinvitiligo.//JEurAcadDermatolVenereol.2007Aug;21(7):865-7697. Khan A.M., Cohen M.J., Kaplan L., et al.
Vitiligo: treatment by epithelialsheet grafting. // J Am Acad Derm, 1995, 33:646-648.98. Khan R., Satyam A., Gupta S., Sharma V.K., Sharma A. Circulatory levelsof antioxidants and lipid peroxidation in Indian patients with generalized andlocalizedvitiligo//ArchDermatolRes.2009Oct;301(10):731-7.doi:10.1007/s00403-009-0964-4.99. Kollner K., Wimmershoff M., Landthaler M., Hohenleutner U. Treatment oforal lichen planus with the 308-nm UVB laser-early preliminary results in eightpatients.
// Lasers Surg Med. 2003; 33 (3): 158—160.100.Kossakowska M.M., Placek W.J. Control of negativ emotions and itsimplication for illness perception among psoriasis and vitiligo patients.// JEADV,2010, vol 24(4): 429-43101.Krüger C., Schallreuter K.U. A review of the worldwide prevalence ofvitiligo in children/adolescents and adults.
Int J Dermatol 2012; 51(10):1206-1212102.Laberge G., Mailloux C.M., Gowan K., Holland P., Bennett D.C.,Fain P.R., Spritz R.A. Early disease onset and increased risk of other autoimmunediseases in familial generalized vitiligo.//Pigment Cell Res. 2005,18,300-305103.LaBerge G.S., Bennett D.C., Fain P.R., Spritz R.A. PTPN22 isgenetically associated with risk of generalized vitiligo, but CTLA4 is not. // J.Invest. Dermatol. 2008.- №128(7).-P.1757-1762.104.Lambe T., Leung J.C., Bouriez-Jones T., Silver K., Makinen K.,108Crockford T.L., Ferry H., Forrester J.V., Cornall R.J. CD4 T cell-dependentautoimmunity against a melanocyte neoantisgen induces pontaneous vitiligo anddepends upon Fas-Fas ligand interactions.// J Immunol.
2006 Sep 1;177(5):305562.105.Lang K.S., Caroli C.C., Muhm A., Wernet D., Moris A., Schittek B.,Knauss-Scherwitz E., Stevanovic S., Rammensee H.G., Garbe C. HLA-A2restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patientsare related to disease activity and are predominantly directed againstMelanA/MART1.// J Invest Dermatol. 2001 Jun;116(6):891-7106.Le Duff F., Fontas E., Giacchero D., Sillard L., Lacour J.P., OrtonneJ.P. et al. 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: arandomized study. Br.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
